FAB classification of myelodysplastic syndromes: merits and controversies

1995 ◽  
Vol 71 (1) ◽  
pp. 3-11 ◽  
Author(s):  
G. E. G. Verhoef ◽  
S. Pittaluga ◽  
C. De Wolf-Peeters ◽  
M. A. Boogaerts
Keyword(s):  
Myelodysplastic Syndromes ◽  
Fab Classification

FAB classification of myelodysplastic syndromes: merits and controversies

1995 ◽  
Vol 71 (1) ◽  
pp. 3-11 ◽  
Author(s):  
G. E. G. Verhoef ◽  
S. Pittaluga ◽  
C. De Wolf-Peeters ◽  
M. A. Boogaerts
Keyword(s):  
Myelodysplastic Syndromes ◽  
Fab Classification

Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7083-7083 ◽  
Author(s):  
R. M. Lyons ◽  
T. Cosgriff ◽  
S. Modi ◽  
H. McIntyre ◽  
C. L. Beach ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Working Group ◽  
Open Label ◽  
Dosing Schedule ◽  
Fab Classification ◽  
Open Label Trial ◽  
Grade 3 ◽  
Treatment Related Mortality ◽  
Related Mortality

7083 Background: At a dosing schedule of 75 mg/m2/day SC for 7 days every 4 weeks, azacitidine is an effective and safe treatment (Tx) for patients (pts) with myelodysplastic syndromes (MDS) (JCO 2002; 20:2429). An alternative dosing schedule that eliminates the need for weekend dosing would be more convenient to pts and clinicians. Methods: In this phase II, multicenter, open-label trial, pts with MDS were randomized to 1 of 3 regimens that were repeated every 4 weeks: AZA 5–2-2 (75 mg/m2/day × 5 days, followed by 2 days no Tx, followed by 75 mg/m2/day × 2 days), AZA 5–2-5 (50 mg/m2/day × 5 days, followed by 2 days no Tx, followed by 50 mg/m2/day × 5 days) or AZA 5 (75 mg/m2/day × 5 days). To determine if response/improvement according to International Working Group criteria (Blood 2000; 96:3671) can be maintained after 6 cycles, the study was amended to include a 12-month maintenance comparing AZA 5 every 4 weeks with AZA 5 every 6 weeks. Results: As of Nov. 30, 2006, 138 pts have been randomized to AZA 5–2-2 (n=46), AZA 5–2-5 (n=47) and AZA 5 (n=45). Most pts are RA (43%) or RAEB (30%), based on FAB classification. Of 104 pts who have received =2 cycles of Tx, hematologic improvement (major or minor in at least 1 cell line) occurred in 63% (65) of the patients ( Table ). Of these pts, 14% had a bi-lineage (AZA 5–2-2: 11%, AZA 5–2-5: 10%, AZA 5: 22%) and 6% had a tri-lineage AZA 5–2-2: 6%, AZA 5–2-5: 7%, AZA 5: 5%) response (based on any improvement). Ongoing pts in the study include AZA 5–2-2: 41% (19/46), AZA 5–2-5: 47% (22/47), and AZA 5: 58% (26/45). No treatment-related mortality has been reported. Most Tx-related grade 3 or 4 events were hematological (AZA 5–2-2: 39%, AZA 5–2-5: 24%, AZA 5: 16%). Updated data, including several pts who have completed at least 6 cycles maintenance, will be available at the time of the meeting. Conclusions: These data indicate that the 3 alternative azacitidine dosing schedules are safe, effective, and similar in efficacy with the FDA-approved regimen. [Table: see text] [Table: see text]

Institutional performance in application of the FAB classification of acute leukemia. The southwest oncology group experience

Cancer ◽  
1985 ◽  
Vol 55 (9) ◽  
pp. 1979-1986 ◽  
Author(s):  
David R. Head ◽  
Catherine M. Craven ◽  
Lizardo Cerezo ◽  
Richard A. Savage ◽  
John N. Bickers ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Institutional Performance ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Fab Classification ◽  
Group Experience

Myelodysplasia

2018 ◽  
Author(s):  
Drew Provan ◽  
Trevor Baglin ◽  
Inderjeet Dokal ◽  
Johannes de Vos ◽  
Mammit Kaur
Keyword(s):  
Prognostic Factors ◽  
Clinical Features ◽  
Myelodysplastic Syndromes ◽  
Response Criteria ◽  
Myeloproliferative Diseases ◽  
Clinical Variants

Myelodysplastic syndromes (MDS) - Classification of MDS - Clinical features of MDS - Prognostic factors in MDS - Clinical variants of MDS - Management of MDS - Response criteria - Myelodysplastic/myeloproliferative diseases (MDS/MPD)

A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes

2017 ◽  
Vol 39 (6) ◽  
pp. 577-584 ◽  
Author(s):  
B. Kárai ◽  
J. Bedekovics ◽  
Zs. Miltényi ◽  
L. Gergely ◽  
L. Szerafin ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Tube Flow ◽  
Single Tube ◽  
Flow Cytometric
Sign in / Sign up

Export Citation Format

Share Document